COMMUNIQUÉS West-GlobeNewswire

ChromaDex Appoints Yan Chu as Managing Director, Asia Pacific
02/10/2018
LOS ANGELES, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Yan Chu as Managing Director, Asia Pacific, effective today. Based in Singapore, Chu will lead the TRU [...]
Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers
02/10/2018
Data from Study Expected in Q1 2019 MONTREAL, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare [...]
Clementia amorce un essai clinique de phase 1 portant sur une formulation de gouttes oculaires à base de palovarotène mené chez des volontaires sains
02/10/2018
Disponibilité prévue des données de l’étude : T1 2019 MONTRÉAL, 02 oct. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des traitements [...]
Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
02/10/2018
Berlin, Germany, 2 October 2018 - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural [...]
Press release: Terveystalo's well-being services grow: Fysiatrinen osaamiskeskus Prima Oy to become part of Terveystalo
02/10/2018
On September 28, Terveystalo signed a contract on acquiring the operations of Fysiatrinen osaamiskeskus Prima Oy. The company's employees will be transferred to Terveystalo as old employees and the operations will [...]
People with diabetes may achieve improved glycaemic control with Tresiba® versus glargine U100, without an increase in hypoglycaemia
02/10/2018
Berlin, Germany, 2 October 2018 - According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA 1c ) with Tresiba ® (insulin [...]
Ryzodeg® offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart
02/10/2018
Berlin, Germany, 2 October 2018 - When treated with once-daily Ryzodeg ® , people with type 2 diabetes achieved similar blood sugar control with half the number of daily injections, significantly lower total daily [...]
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
02/10/2018
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic [...]
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
02/10/2018
Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes Funding enables further acceleration of commercial expansion and R&D programs EUR 3.5 million of first tranche of [...]
Shire plc: Rule 2.9 Announcement
02/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 2 October 2018 [...]
genedrive to release Genedrive® Connect mobile app
02/10/2018
For release: 2 October genedrive plc ("genedrive" or the "Company") genedrive to release Genedrive® Connect mobile app genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces phase 1 [...]
Addex to Present at the Sachs 18th Annual Biotech in Europe Forum
02/10/2018
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will participate in the [...]
Shareholder Update Q3 2018
02/10/2018
Highlights: Venous leg ulcer Phase 2 trial on track: top-line results mid-November Diabetic foot ulcer pilot clinical study: in development with key US researchers Ocular wounds: international patent applications filed [...]
Canada House Wellness Group Reports First Quarter Fiscal Year 2019 Results
02/10/2018
49% Increase in Revenue compared to the same Period in the Prior Year NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Canada House Wellness [...]
Eve & Co Files Financial Results for the Three and Nine Month Periods Ended July 31, 2018
02/10/2018
TORONTO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve”) (TSXV: EVE) is pleased to announce that it has filed its interim financial results for the three and nine month periods ended [...]
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
02/10/2018
WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be presented at the Society for [...]
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
02/10/2018
CAMBRIDGE, Mass. and BEIJING, China, Oct. 01, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Assure Holdings Announces Option Issuance
02/10/2018
DENVER, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announces that it has issued an aggregate of [...]
Neon Therapeutics to Present at the Society for Immunotherapy of Cancer 33rd Annual Meeting
01/10/2018
CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at [...]

Pages